Photo Release -- Complete Genomics Whole Genome Sequencing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Photo Release -- Complete Genomics Whole Genome Sequencing Enables Discovery of Point Mutation Responsible for Prader-Willi Syndrome

MOUNTAIN VIEW, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (formerly NASDAQ: GNOM) ("Complete"), a wholly-owned subsidiary of BGI-Shenzhen, a leading international genomics organization based in Shenzhen, China, today announced that its highly-accurate whole genome sequencing technology played a pivotal role in identifying a point mutation that causes Prader-Willi Syndrome (PWS). That discovery helped resolve a diagnostic conundrum for four young male patients. These data were published today in Nature Genetics .

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=21224

PWS is a rare genetic disorder that causes poor muscle tone, low levels of sex hormones, and a constant feeling of hunger, according to the Eunice Kennedy Shriver National Institute of Child Health and Human Development. As a result, people with this condition tend to overeat, leading to obesity.

The first patient in this study was tested for PWS when he was one year old, but the result was negative. Over the next 12 years, he began to manifest some, but not all, of the typical PWS symptoms.

Then the patient met with paper author Dr. C. Thomas Caskey, who was director and chief executive officer of the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, part of the University of Texas Health Science Center at Houston. Dr. Caskey has since joined Baylor College of Medicine as professor of molecular and human genetics.

It was Dr.Caskey who referred the patient to Dr. Christian Schaaf, an assistant professor of molecular and human genetics at Baylor College of Medicine, and faculty member at the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, a co-lead author on the paper. Dr. Schaaf evaluated the patient and confirmed the earlier findings. Dr. Schaaf then used Complete's highly-accurate whole genome sequencing service to determine the genetic basis of his patient's symptoms.

Those sequencing results were reviewed by fellow co-lead author Dr. Manuel L. Gonzalez-Garay, an assistant professor and a bioinformatics expert at the University of Texas Health Science Center at Houston's Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases. Dr. Gonzalez-Garay identified a single mutation, a base deletion, on the protein-coding MAGEL2 gene in a section of chromosome 15 that had been previously linked to PWS. It proved to be a frame-shift deletion mutation in a difficult to sequence GC rich region, which disrupts the activity of the MAGEL2 protein product.

As MAGEL2 is only expressed on the paternal gene, it was important to determine whether the mutation was on the maternal or paternal version of chromosome 15. In this case, the MAGEL2 mutation was confirmed to be on the paternal gene using a modified version of Complete Genomics' Long Fragment Read technology.

To investigate MAGEL2 's role in this disease further, the researchers reviewed more than 1,200 exome sequencing reports from the Baylor Whole Genome Sequencing Laboratory, searching for other patients with point mutations on that gene. They identified three additional patients – one had classic PWS and the other two had PWS-like symptoms. However, they all had negative PWS tests as infants. All four patients were also diagnosed with autism spectrum disorder and intellectual disability.

"This is the first study to show that point mutations can cause Prader-Willi Syndrome," said Dr. Schaaf. "This is an important development that increases our understanding of this complex disorder, and also gives four boys a diagnosis, which they and their parents have sought for many years."

"It also underscores the importance of being able to distinguish between maternal and paternal variants because only patients who had point mutations on the paternal copy of the MAGEL2 gene would experience the disorder," said Dr. Brock Peters, director of research at Complete Genomics, Inc.

PWS occurs in males and females equally and affects all races, according to the Prader-Willi Syndrome Association . Estimates of the incidence of PWS have ranged from 1:8,000 to 1:25,000 with the most likely figure being 1:15,000, it adds.

About Complete

Complete Genomics is a leader in accurate whole human genomic sequencing. Using our proprietary sequencing instruments, chemistry, and software, we have sequenced more than 15,000 whole human genomes for our research customers over the past three years. Our mission is to provide the technology for sequencing one million human genomes, enabling researchers and clinicians to improve human health through the prevention, diagnosis, and treatment of genetic diseases and conditions. Additional information can be found at www.completegenomics.com .

Complete Contact Denise Kruse Senior Marketing Manager +1 (650) 943-2654 Baylor College of Medicine Contact Glenna Picton +1 (713) 798-4710 Media Contact Lisa Osborne Rana Healthcare Solutions +1 (206) 992-5245

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 14

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 9

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 14

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 17

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 12

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 11

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 8

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 11

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 12

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Semtech Corporation Faces Legal Challenge: Shareholder Rights Explained

Updated Category News Views 145

Understanding the Current Legal Landscape for Semtech Corporation Semtech Corporation, a notable player in the semiconductor industry, is currently embroiled in a significant class action lawsuit concerning alleged violations of federal securities laws. This legal action has garnered the attention of investors and shareholders alike, prompting them to seek clarity on...

Continue Reading
Breezeline Expands Fiber Internet Access in New Hampshire

Updated Category News Views 194

Breezeline's Commitment to Fiber Internet Expansion Breezeline is actively enhancing its service offerings by deploying fiber-to-the-home internet in several communities across New Hampshire. This exciting initiative aims to connect towns such as Barnstead, Farmington, Franklin, Milton, Northfield, Pittsfield, Rochester, Tilton, and Wolfeboro with high-speed internet. As...

Continue Reading
Investigation into Cepton, Inc.'s Share Sale: What's Next for Investors?

Updated Category News Views 78

Cepton, Inc. (NASDAQ: CPTN) got itself tangled in a mess back when it sold to KOITO MANUFACTURING CO., LTD. for $3.17 per share. Traders were quick on the draw as Halper Sadeh LLC kicked off an investigation into whether that price was just or a complete rip-off for shareholders. The heart of the issue? Was Cepton’s board really looking out for their shareholders’...

Continue Reading
Affordable 5G Solutions for Low-Income Households Set to Transform Lives

Updated Category News Views 218

Mission Telecom Partners with Computers 4 People This innovative partnership is set to eliminate significant barriers to affordable broadband for low-income households. By dramatically reducing hardware costs, these organizations aim to transform internet access across communities. An Unprecedented Move Towards Digital Equity The collaboration between Mission Telecom and...

Continue Reading
KPN's Strategy and Progress on €250 Million Share Buyback

Updated Category News Views 139

KPN's Strategic Share Buyback Initiative KPN is making notable strides with its €250 million share buyback program. Recently, the company repurchased a significant amount of its ordinary shares from March 24 to March 28. This specific buyback involved 2,020,000 shares, purchased at an average price of €3.84 per share, totaling approximately €7.8 million. These...

Continue Reading